



Outset Medical Appoints New General Counsel

June 4, 2020

Outset Medical, a leading med tech innovator delivering first-of-its-kind technology into the growing global dialysis market, today announced the appointment of John Brottem as the company's new General Counsel.

"We are thrilled to have John join our team as General Counsel," said Outset Medical's Chief Executive Officer, Leslie Trigg. "John's capability and expertise in supporting the legal needs of high growth companies will be invaluable to Outset."

Mr. Brottem brings nearly two decades of experience leading legal teams within the healthcare and technology industries. John joined the company from Omnicell where he most recently served as Vice President and Deputy General Counsel. At Omnicell, John was involved in a range of activities including public company reporting, corporate governance, M&A and strategic transactions, sales and marketing support, compliance, regulatory, IP and litigation. He previously served as corporate counsel at Brocade Communications Systems and Foundry Networks and spent six years as an associate in the business department of Cooley LLP.

John received his undergraduate degree from Occidental College and his JD from the University of California, Davis, School of Law.

"I am excited about joining Outset; a company that is disrupting the dialysis market and poised for momentous growth," said Mr. Brottem. "I look forward to working with the team at Outset in support of the company's continued success, growth, and commitment to dialysis patients."

Dialysis is delivered to more than 550,000 U.S. patients several times per week to remove waste products and excess fluid from patients with kidney failure. Although more than 85 million dialysis treatments take place in the United States each year at an estimated annual cost of ~\$75 billion, little meaningful technology or service model innovation has been introduced in decades.

Outset Medical's Tablo was designed as an enterprise solution to reduce the cost and complexity of dialysis, while improving the experience for patients and providers. With real-time water purification and dialysis fluid production integrated in a single, compact system, Tablo functions like a dialysis clinic on wheels. Requiring just an electrical outlet and tap water to operate, Tablo frees providers from having to rely on expensive clinic infrastructure, enabling on-demand, cost-effective dialysis in a range of use environments. Tablo was designed to look and feel like an intuitive consumer product, keeping end-user simplicity in mind. Wireless data, sensor-based automation, and an animated touchscreen make Tablo easy to learn and use for healthcare professionals and patients alike.

Media Contact

Kevin Knight
206.451.4823
media@outsetmedical.com

About the Tablo Hemodialysis System

Tablo is an FDA-cleared enterprise solution for dialysis, designed specifically to reduce the cost and complexity of dialysis across all care settings. Requiring only an electrical outlet and tap water to operate, the mobile Tablo system frees patients and providers from the burdensome infrastructure required to operate conventional dialysis machines. The machine's integrated functionality enables it to serve as a dialysis clinic on wheels and enables providers to standardize to a single platform that can be used across a wide spectrum of care settings. Wireless data, sensor-based automation and an animated touchscreen make the system easy to learn and use. Leading health systems and medical centers across the U.S. have adopted Tablo for hospital and clinic dialysis, and the U.S. Department of Health and Human Services (HHS) awarded a contract for the use of Tablo in communities hit by natural disasters.

About Outset Medical

Outset Medical is dedicated to technology-driven service model innovation aimed at reducing cost and transforming the patient care experience. Outset's Tablo System is FDA-cleared for use in acute and chronic care settings. In addition to its acute and chronic care commercial expansion, the company has concluded a clinical trial to expand Tablo's labeled indication to include home use. For more information visit www.outsetmedical.com and follow the company on Twitter at @OutsetMedical.